Free Trial
CNSX:BUX

Biomark Diagnostics (BUX) Stock Price, News & Analysis

Biomark Diagnostics logo

About Biomark Diagnostics Stock (CNSX:BUX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
11,500 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Remove Ads
Receive BUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomark Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BUX Stock News Headlines

Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Headlines

BUX Stock Analysis - Frequently Asked Questions

Shares of BUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomark Diagnostics investors own include Stantec (STN) and IQE (IQE).

Industry, Sector and Symbol

Stock Exchange
CNSX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
CNSX:BUX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Stocks Set to Soar in Spring 2025 Cover

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

This page (CNSX:BUX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners